Recommended Free Tools
Researchers have identified a way cancer cells may depend on to maintain extrachromosomal DNA (ecDNA): a repair process involving the enzyme Polθ. In laboratory models, blocking that process destabilized ecDNA and impaired the fitness of cells that relied on it. The finding points to a possible vulnerability, not a proven cancer treatment.
What is ecDNA?
Extrachromosomal DNA, or ecDNA, is circular DNA that exists outside the chromosomes. It can carry amplified oncogenes—genes that help drive cancer growth. The 2026 Nature study’s authors estimate that ecDNA occurs in about 17% of human cancers. Across populations, ecDNA is associated with tumor diversity, aggressive behavior, treatment resistance and poorer outcomes; those associations do not mean every ecDNA-positive cancer behaves the same way.
Unlike DNA arranged within chromosomes, ecDNA can vary among cells in a tumor. That variation can contribute to tumor heterogeneity, but it also creates a potential weakness: the circles must survive damage and be maintained as cancer cells divide.
How does the proposed vulnerability work?
The study, “MMEJ repair of breaks at TA repeats maintains ecDNA and cancer fitness,” was published in Nature on 23 September 2026. It describes a chain of events involving fragile regions of ecDNA and two DNA-maintenance mechanisms.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →- TA-rich regions are prone to breaks. The researchers identified stretches rich in the DNA sequence TA as breakage hotspots on ecDNA.
- FANCM helps prevent damage. The protein FANCM can resolve problematic DNA structures and suppress break formation.
- Polθ-mediated repair helps maintain ecDNA. Breaks that escape FANCM’s surveillance can be cleaved by the ERCC1–ERCC4 complex, then repaired through Polθ-mediated microhomology-mediated end joining (MMEJ).
- Blocking Polθ disrupts the circles. In experimental systems, Polθ inhibition led to ecDNA-specific damage, depletion of ecDNA and its sequestration into micronuclei—small structures that can form when damaged DNA is excluded from a cell’s main nucleus.
In other words, the proposed weakness is not that ecDNA never breaks. It is that some cancer cells appear to rely on a particular repair route to keep ecDNA intact when breaks occur.
What did the experiments show?
The study reports molecular and cell-based experiments, including comparisons between ecDNA-positive cells and relevant controls. The researchers tested cell lines from prostate, gastric and colorectal cancers. They found that inhibiting Polθ selectively depleted ecDNA in the experimental systems, caused ecDNA-specific damage and impaired the fitness of cells dependent on ecDNA.
Rank #2
Single-cell sequencing also indicated structural instability, while analysis of human tumor sequencing data found enrichment of rearrangements at TA repeats. That tumor-data analysis supports the relevance of the proposed breakage pattern in human cancers; it is not a clinical test of a drug or evidence that patients benefit from Polθ inhibition.
How do FANCM and Polθ differ as intervention points?
| Intervention point | Role in the study’s model | Evidence reported |
|---|---|---|
| FANCM | Helps prevent breaks by resolving problematic DNA structures. | Disrupting FANCM together with Polθ increased ecDNA instability in experiments. |
| Polθ / MMEJ | Repairs certain breaks after they occur. | Polθ inhibition destabilized and depleted ecDNA in tested experimental systems. |
The combined FANCM–Polθ result supports a mechanism for further investigation. It does not establish a combination treatment, its safety, or a benefit for patients.
Rank #3
Does this mean there is a treatment for patients?
No. The study presents preclinical evidence from molecular and cell experiments, alongside analysis of human tumor sequencing data. It does not demonstrate that a Polθ inhibitor treats cancer patients, improves outcomes or is approved for targeting ecDNA.
Polθ inhibitors may be in clinical development for other contexts, but this paper does not establish that they are approved, effective, or being clinically tested specifically as an ecDNA-targeting strategy. The finding should not be taken as a reason to seek or use an inhibitor.
A Memorial Sloan Kettering Cancer Center-authored news account quoted study leader Agnel Sfeir, PhD, saying, “We were surprised to find that ecDNA has a built-in fragility.” The same account quoted Sfeir: “There’s still much to learn, but we’re excited to see where the discovery of this vulnerability can take us.” Those remarks, reported by SciTechDaily on 2 October 2026, reflect the discovery’s promise and its early stage.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
